

## Literatura ACTA MEDICINAE 1/2017 Biologická léčba

- 2 **Současný pohled na belimumab v léčbě systémového lupus erythematoses**  
MUDr. Zdenka Hrušková, Ph.D. | MUDr. Barbora Svobodová | prof. MUDr. Vladimír Tesař, DrSc.  
Klinika nefrologie VFN a 1. LF UK, Praha
- 2 **Nová evropská doporučení pro léčbu axiálních spondyloartritid**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Účinnost inhibitorů TNF $\alpha$  a perzistence k jejich užívání u osob s ankylozující spondylitidou**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 3 **Dosud nenaplněné terapeutické cíle v léčbě revmatoidní artritidy**  
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 3 **Denosumab v terapii osteoporózy**  
MUDr. Jan Rosa Affidea Praha, s. r. o., Praha-Chodov
- 4 **Adalimumab a jeho role jako blokátoru centrálního cytokinu – TNF**  
MUDr. Zdeněk Antal Kožní oddělení, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha, Fakulta vojenského zdravotnictví v Hradci Králové, Univerzita obrany, Brno
- 4 **Biologická léčba psoriázy u pacienta s latentní tuberkulózní infekcí – kazuistika**  
MUDr. Olga Filipovská Kožní oddělení Masarykovy nemocnice v Ústí nad Labem, o. z., Krajská zdravotní, a. s.
- 4 **Obinutuzumab v iniciační léčbě starších a komorbidních nemocných s chronickou lymfocytární leukemií**  
prof. MUDr. Tomáš Papajík, CSc. | MUDr. Renata Urbanová, Ph.D. Hemato-onkologická klinika LF UP a FN Olomouc
- 5 **Nivolumab v léčbě Hodgkinova lymfomu – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha  
Komentář k článku: prof. MUDr. Marek Trněný, CSc. I. interní klinika, 1. LF UK a VFN, Praha
- 5 **Léčba mnohočetného myelomu – současné možnosti**  
prof. MUDr. Ivan Špička, CSc. I. interní klinika 1. LF UK a VFN, Praha
- 6 **Biosimilární rituximab – GP2013 – lékový profil**  
MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové
- 6 **Možnosti léčby metastazujícího melanomu v kazuistikách**  
MUDr. Ivana Krajsová, MBA Kožní klinika VFN a 1. LF UK, Praha
- 6 **Biologická léčba karcinomu prsu aktuálně**  
MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 7 **Palbociclib v kombinaci s letrozolem v léčbě diseminovaného karcinomu prsu**  
MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno  
Komentář k článku: MUDr. Katarína Petránková, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno
- 7 **Osimertinib – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 7 **Monoklonální protilátky v léčbě nemalobuněčného karcinomu plic**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha
- 8 **Alectinib – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 8 **Renální karcinom – novinky v biologické léčbě 2016**  
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 8 **Biologická léčba kolorektálního karcinomu**  
MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno
- 9 **Biologická léčba roztroušené sklerózy**  
doc. MUDr. Radomír Taláb, CSc. Neurologická klinika LF UK a FN Plzeň  
MUDr. Marika Talábová Neurologická klinika LF UK a FN Hradec Králové
- 9 **Biologická léčba hypercholesterolemie**  
prof. MUDr. Richard Češka, CSc. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha |  
Ing. Lucie Votavová ScreenPro FH, z. s., Praha | MUDr. Michaela Šnejdrlová, Ph.D. |  
MUDr. Martina Vaclová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha |  
Ing. Tatjana Aleksičová ScreenPro FH, z. s., Praha | doc. MUDr. Michal Vrablík, Ph.D.  
Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 9 **Hepatitida C – lékové interakce přímo působících antihepatitik**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

# Současný pohled na belimumab v léčbě systémového lupus erythematosides

MUDr. Zdenka Hrušková, Ph.D. | MUDr. Barbora Svobodová | prof. MUDr. Vladimír Tesař, DrSc.

Klinika nefrologie VFN a 1. LF UK, Praha

- 1 Van Vollenhoven, R. F. – Mosca, M. – Bertias, G., et al.: Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *Ann Rheum Dis*, 2014, 73, s. 958–967.
- 2 Bruce, I. N. – O’Keefe, A. G. – Farewell, V., et al.: Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis*, 2015, 74, s. 1706–1713.
- 3 Ruiz-Arruz, I. – Ugarte, A. – Cabezas-Rodríguez, I., et al.: Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. *Rheumatology (Oxford)*, 2014, 53, s. 1470–1476.
- 4 Tarzi, R. M. – Mason, J. C. – Pusey, C. D.: Issues in trial design for ANCA-associated and large-vessel vasculitis. *Nat Rev Rheumatol*, 2014, 10, s. 502–510.
- 5 Franklyn, K. – Hoi, A. – Nikpour, M., et al.: The need to define treatment goals for systemic lupus erythematosus. *Nat Rev Rheumatol*, 2014, 10, s. 567–571.
- 6 Hrušková, Z. – Tesař, V.: Biologická léčba systémového lupus erythematosides. *ACTA MEDICINAE*, 2014, 3, s. 17–18.
- 7 Tesař, V. – Hrušková, Z.: Treatment of proliferative lupus nephritis: a slowly changing landscape. *Nat Rev Nephrol*, 2011, 7, s. 96–109.
- 8 Wallace, D. J. – Stohl, W. – Furie, R. A., et al.: A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. *Arthritis Rheum*, 2009, 61, s. 1168–1178.
- 9 Navarra, S. V. – Guzmán, R. M. – Gallacher, A. E., et al.: BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*, 2011, 377, s. 721–731.
- 10 Furie, R. – Petri, M. – Zamani, O., et al.: BLISS-76 Study Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2011, 63, s. 3918–3930.
- 11 Stohl, W. – Hiepe, F. – Latinis, K. M., et al.: Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2012, 64, s. 2328–2337.
- 12 Manzi, S. – Sánchez-Guerrero, J. – Merillo, J. T., et al.: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. *Ann Rheum Dis*, 2012, 71, s. 1833–1838.
- 13 Strand, V. – Levy, R. A. – Cervera, R., et al.: Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. *Ann Rheum Dis*, 2014, 73, s. 838–844.
- 14 Bruce, I. N. – Urowitz, M. – van Vollenhoven, R., et al.: Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. *Lupus*, 2016, 25, s. 699–709.
- 15 Van Vollenhoven, R. F. – Petri, M. – Wallace, D. J., et al.: Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. *Arthritis Rheumatol*, 2016, 68, s. 2184–2192.
- 16 Dooley, M. A. – Houssiau, F. – Aranow, C., et al.: BLISS-52 and -76 Study Groups: Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. *Lupus*, 2013, 22, s. 63–72.
- 17 Collins, C. E. – Dall’Era, M. – Kan, H., et al.: Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSERVE study in the USA. *Lupus Sci Med*, 2016, 3, s. e000118.
- 18 Hui-Yuen, J. S. – Reddy, A. – Taylor, J., et al.: Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. *J Rheumatol*, 2015, 42, s. 2288–2295.
- 19 Iaccarino, L. – Bettio, S. – Reggia, R., et al.: Belimumab decreases flare rate and Hinders the expected damage progression in patients with active systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*, 7, 7, 2016, doi: 10.1002/acr.22971.
- 20 Scheinberg, M. – de Melo, F. F. – Bueno, A. N., et al.: Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. *Clin Rheumatol*, 2016, 35, s. 1719–1723.
- 21 Schwarting, A. – Schroeder, J. O. – Alexander, T., et al.: First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSERVE Germany Study. *Rheumatol Ther*, 2016, 3, s. 271–290.
- 22 Furer, V. – Zisman, D. – Pokroy-Shapira, E., et al.: Systemic lupus erythematosus exacerbation following cessation of belimumab treatment. *Scand J Rheumatol*, 2016, 45, s. 103–106.
- 23 Ginzler, E. M. – Wallace, D. J. – Merillo, J. T., et al.: LBSL02/99 Study Group: Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. *J Rheumatol*, 2014, 41, s. 300–309.
- 24 Fredericks, C. – Kvam, K. – Bear, J., et al.: A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. *Lupus*, 2014, 23, s. 711–713.
- 25 Sheikh, S. Z. – Hamer, A. E. – Fox, N. L., et al.: Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus. *Int J Clin Pharmacol Ther*, 26, 9, 2016, Epub před tiskem.
- 26 Bengtsson, A. A.: Belimumab in systemic lupus erythematosus – what can be learned from longterm observational studies? *J Rheumatol*, 2014, 41, s. 192–193.
- 27 Sanchez-Niño, M. D. – Ortiz, A.: That Obscure Object of Desire: in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. *Nephrol Dial Transplant*, 2015, 30, s. 394–400.

## Nová evropská doporučení pro léčbu axiálních spondyloartritid

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Zochling, J. – van der Heijde, D. – Burgos-Vargas, R., et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*, 2006, 65, s. 442–452.
- 2 Braun, J. – van der Berg, R. – Baraliakos, X., et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*, 2011, 70, s. 896–904.
- 3 van der Heijde, D. – Ramiro, S. – Landewé, R., et al.: 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Abstrakt ACR*, 2016, č. 1045.
- 4 Pavelka, K.: Doporučení České reumatologické společnosti pro léčbu ankylozující spondylitidy. *Čes Revmatol*, 2012, 1, s. 4–11.
- 5 Závada, J. – Uher, M. – Šisol, K. – Forejtová, Š. – Jarošová, K. – Mann, H. – Vencovský, J. – Pavelka, K.: A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. *Ann Rheum Dis*, 2016, 75, s. 96–102.
- 6 Braun, J. – Baraliakos, X. – Deodhar, A., et al.: Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. *Ann Rheum Dis*, 13, 12, 2016, pii: annrheumdis-2016-209730, doi: 10.1136/annrheumdis-2016-209730.
- 7 Sieper, J. – Deodhar, A. – Marzo-Ortega, H., et al.: Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis*, 31, 8, 2016, pii: annrheumdis-2016-210023, doi: 10.1136/annrheumdis-2016-210023.
- 8 Braun, J. – Brandt, J. – Listing, J., et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet*, 2002, 359, s. 1187–1193.
- 9 Baraliakos, X. – Listing, J. – Brandt, J., et al.: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther*, 2005, 7, s. R439–R444.
- 10 Boonen, A. – van der Linden, S. M.: The burden of ankylosing spondylitis. *J Rheumatol Suppl*, 2006, 78, s. 4–11.
- 11 Baeten, D. – De Keyser, F. – Mielants, H., et al.: Ankylosing spondylitis and bowel disease. *Best Pract Res Clin Rheum*, 2002, 16, s. 537–549.
- 12 Rudwaleit, M. – Bratrem, D.: Ankylosing spondylitis and bowel disease. *Best Pract Res Clin Rheumatol*, 2006, 20, s. 451–471.
- 13 Brophy, S. – Calin, A.: Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. *J Rheumatol*, 2001, 28, s. 2283–2288.
- 14 Baillet, A. – Gossec, L. – Garmond, L., et al.: Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. *Ann Rheum Dis*, 2016, 75, s. 965–973.
- 15 van der Heijde, D. – Landewé, R. B. – Mease, P. J., et al.: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. *Arthritis Rheum*, 2016, 68, s. 1914–1921.
- 16 van der Heijde, D. – Ramiro, S. – Landewé, R., et al.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*, 2017, 0, s. 1–14.

## Účinnost inhibitorů TNF $\alpha$ a perzistence k jejich užívání u osob s ankylozující spondylitidou

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Heinonen, A. V. – Aaltonen, K. J. – Joensuu, J. T., et al.: Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. *J Rheumatol*, 2015, 42, s. 2339–2346.

# Dosud nenaplněné terapeutické cíle v léčbě revmatoidní artritidy

MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- Lee, D. M. – Weinblatt, M. E.: Rheumatoid arthritis. *Lancet*, 2001, 358, s. 903–911.
- Singh, J. A. – Saag, K. G. – Bridges, S. L. Jr; American College of Rheumatology: 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res* (Hoboken), 2016, 68, s. 1–25.
- Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update *Annals of the Rheumatic Diseases*. Poprvé publikováno 6. 3. 2017, doi: 10.1136/annrheumdis-2016-210715.
- Kievit, W. – Fransen, J. – de Waal Malefijt, C. M., et al.: Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. *Rheumatology (Oxford)*, 2013, 52, s. 1500–1508.
- Austad, C. – Kvien, T. K. – Olsen, I. C., et al.: Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register. *An Rheum Dis*, 2015, 74, s. 148–155.
- Haugeberg, G. – Hansen, I. J. – Soldal, D. M., et al.: Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. *Arthritis Res Ther*, 2015, 17, s. 219.
- Pincus, T. – Brooks, R. H. – Callahan, L. F.: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. *Ann Intern Med*, 1994, 120, s. 26–34.
- Gabriel, S. E. – Michaud, K.: Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. *Arthritis Res Ther*, 2009, 11, s. 229.
- Panoulas, V. F. – Douglas, K. M. J. – Milonias, H. J., et al.: Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2007, 46, s. 1477–1482.
- Crowson, C. S. – Nicola, P. J. – Kremers, H. M., et al.: How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? *Arthritis Rheum*, 2005, 52, s. 3039–3044.
- Gerhold, K. – Richter, A. – Schneider, M., et al.: Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. *Rheumatology (Oxford)*, 2015, 54, s. 10.
- Kosinski, M. – Kujawski, S. C. – Martin, R., et al.: Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. *Am J Manag Care*, 2002, 8, s. 231–240.
- Torrance, G. W. – Tugwell, P. – Amorosi, S., et al.: Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. *Rheumatology*, 2004, 43, s. 712–718.
- Amarilyo, G. – Woo, J. M. – Furst, D. E., et al.: Publication outcomes of abstracts presented at an American College of Rheumatology / Association of Rheumatology Health Professionals annual scientific meeting. *Arthritis Care Res* (Hoboken), 2013, 65, s. 622–629.
- Finckh, A. – Escher, M. – Liang, M. H. – Bansback, N.: Preventive treatments for rheumatoid arthritis: issues regarding patient preferences. *Curr Rheumatol Rep*, 2016, 18, s. 51.
- Bansback, N. – Trenaman, L. – Harrison, M.: How important is mode of administration in treatments for rheumatic diseases and related conditions? *Curr Rheumatol Rep*, 2015, 17, s. 514.

## Denosumab v terapii osteoporózy

MUDr. Jan Rosa Affidea Praha, s. r. o., Praha-Chodov

- Colman, E. G.: The Food and Drug Administration's osteoporosis guidance document: past, present and future. *J Bone Miner Res*, 2003, 18, s. 1125–1128.
- Black, D. M. – Cummings, S. R. – Karaf, D. B., et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet*, 1996, 348, s. 1535–1541.
- Black, D. M. – Bauer, D. C. – Schwarz, A. V., et al.: Continuing bisphosphonate treatment for osteoporosis – for whom and for how long? *N Engl J Med*, 2012, 366, s. 2051–2053.
- Cooper, C. – Reginster, J.-Y. – Cortet, B., et al.: Long-term treatment of osteoporosis in postmenopausal women: a review from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the International osteoporosis foundation (IOF). *Current Medical Research & Opinion*, 2012, 28, s. 1–17.
- Kanis, J. A. – McCloskey, E. V. – Johansson, H., et al.: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int*, 2013, 24, s. 23–57.
- Adler, R. A. – El-Hajj Fuleihan, G. – Bauer, D. C., et al.: Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American society for bone and mineral research. *J Bone Miner Res*, 2016, 31, s. 16–35.
- Lipton, A. – Goessl, G.: Clinical development of anti-RANKL therapies for prevention and treatment of bone metastasis. *Bone*, 2011, 48, s. 96–99.
- Freemantle, N. – Satram-Hoang, S. – Tang, E. T., et al.: Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. *Osteoporos Int*, 2012, 23, s. 317–326.
- Cummings, S. R. – San Martin, J. – McClung, M. R., et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*, 2009, 361, s. 756–765.
- Ferrari, S. – Adachi, J. D. – Lippuner, K., et al.: Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. *Osteoporos Int*, 2015, 26, s. 2763–2771.
- Papapoulos, S. – Lippuner, K. – Roux, C., et al.: The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. *Osteoporos Int*, 2015, 26, s. 2773–2783.
- Bone, H. G. – Brandi, M. L. – Brown, J. P., et al.: Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial, ASBMR, Seattle, WA; 12. 10. 2015, #LB-1157.
- Broker, P. J. – Holloway, D. L. – Rasmussen, A. S., et al.: A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. *J Bone Miner Res*, 2004, 19, s. 1059–1066.
- Miller, P. D. – Bolognese, M. A. – Lewiecki, E. M., et al.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. *Bone*, 2008, 43, s. 222–229.
- Bone, H. G. – Bolognese, M. A. – Yuen, C. K., et al.: Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab*, 2011, 96, s. 972–980.
- Aubry-Rozier, B. – Gonzalez-Rodriguez, E. – Stoll, D., et al.: Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. *Osteoporos Int*, 2016, 27, s. 1923–1925.
- Popp, A. W. – Zysset, P. K. – Lippuner, K.: Rebound-associated vertebral fractures after discontinuation of denosumab – from clinic and biomechanics. *Osteoporos Int*, 2016, 27, s. 1917–1921.
- Anastasilakis, A. D. – Makras, P.: Multiple clinical vertebral fractures following denosumab discontinuation. *Osteoporos Int*, 2016, 27, s. 1929–1930.
- Lamy, O. – Gonzalez-Rodriguez, E. – Stoll, D., et al.: Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. *J Clin Endocrinol Metab*, 2016, doi: 10.1210/jc.2016-3170.
- Athanasios, D. – Anastasilakis, A. D. – Polyzos, S. A., et al.: Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. *J Bone Miner Res*, 2017, DOI: 10.1002/jbmr.3110.
- Brown, J. P. – Roux, C. – Törring, O., et al.: Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. *J Bone Miner Res*, 2013, 28, s. 746–752.
- Costa, A. G. – Bilezikian, J. P.: How long to treat with denosumab. *Curr Osteoporos Rep*, 2015, 13, s. 415–420.
- McClung, M. R.: Cancel denosumab holiday. *Osteoporos Int*, 2016, 27, s. 1677–1682.
- Smith, M. R. – Egerdie, B. – Hernández Toriz, N., et al.: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med*, 2009, 361, s. 745–755.
- Orwoll, E. – Teglbjærg, C. S. – Langdahl, B. L., et al.: A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. *J Clin Endocrinol Metab*, 2012, 97, s. 3161–3169.
- Langdahl, B. L. – Teglbjærg, C. S. – Ho, P.-R., et al.: A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. *J Clin Endocrinol Metab*, 2015, 100, s. 1335–1342.
- Tsai, J. N. – Uihlein, V. – Lee, H., et al.: Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. *Lancet*, 2013, 382, s. 50–56.
- Benjamin, Z. – Leder, B. Z. – Tsai, J. N., et al.: Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. *Lancet*, 2015, 386, s. 1147–1455.

# Adalimumab a jeho role jako blokátoru centrálního cytokinu – TNF

MUDr. Zdeněk Antal Kožní oddělení, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha, Fakulta vojenského zdravotnictví v Hradci Králové, Univerzita obrany, Brno

- 1 Nestle, F. O. – Kaplan, D. H. – Barker, J.: Psoriasis. *N Engl J Med*, 2009, 361, s. 496–509.
- 2 Blauvelt, A. – Armstrong, A. W. – Krueger, G. G.: Essential truths for the care and management of moderate-to-severe psoriasis. *J Drugs Dermatol*, 2015, 14, s. 805–812.
- 3 Sampogna, F. – Tabolli, S. – Abeni, D.; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators: Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. *Acta Derm Venereol*, 2012, 92, s. 299–303.
- 4 Davidovici, B. B. – Sattar, N. – Prinz, J., et al.: Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *J Invest Dermatol*, 2010, 130, s. 1785–1796.
- 5 Armuzzi, A. – Lionetti, P. – Blandizzi, C., et al.: Anti-TNF agents as the therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. *Int J Immunopathol Pharmacol*, 2014, 27, s. 11–32.
- 6 Zaba, L. C. – Cardinale, I. – Gilleaudeau, P., et al.: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. *J Exp Med*, 2007, 204, s. 3183–3194.
- 7 Coondoo, A.: Cytokines in dermatology – a basic overview. *Indian J Dermatol*, 2011, 56, s. 368–374.
- 8 Arenberger, P. – Buchtová, L. – Hladovec, J.: Increase of endothelial leucemia in psoriasis. *Acta Dermatovenerol*, 1993, 73, s. 35–36.
- 9 Kouris, A. – Pistiki, A. – Katoulis, A., et al.: Proinflammatory cytokine responses in patients with psoriasis. *Eur Cytokine Netw*, 2014, 25, s. 63–68.
- 10 Vašků, V.: Komorbidita u psoriázy, nový pohled na staré onemocnění. *Dermatol Prax*, 2009, 3, s. 102–104.
- 11 Mease, P. J. – Armstrong, A. W.: Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. *Drugs*, 2014, 74, s. 423–441.
- 12 Kuek, A. – Hazleman, B. L. – Ostor, A. J.: Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. *Postgrad Med J*, 2007, 83, s. 251–260.
- 13 Dregan, A. – Charlton, J. – Chowiec, P., et al.: Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. *Circulation*, 2014, 130, s. 837–844.
- 14 Li, W. Q. – Han, J. L. – Chan, A. T., et al.: Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. *Ann Rheum Dis*, 2013, 72, s. 1200–1205.
- 15 Partsch, G. – Steiner, G. – Leeb, B. F., et al.: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. *J Rheumatol*, 1997, 24, s. 518–523.
- 16 Blandizzi, C. – Gionchetti, P. – Armuzzi, A., et al.: The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. *Int J Immunopathol Pharmacol*, 2014, 27, s. 1–10.
- 17 Liu, Y. – Yang, G. – Zhang, J., et al.: Anti-TNF-alpha monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. *Int Immunopharmacol*, 2015, 28, s. 731–743.
- 18 Gunther, C. – Blau, K. – Foerster, U., et al.: Reduction of inflammatory slan (6-sulfo LacNAc) dendritic cells in psoriatic skin of patients treated with etanercept. *Exp Dermatol*, 2013, 22, s. 535–540.
- 19 Balato, A. – Schiattarella, M. – Di Caprio, R., et al.: Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. *J Eur Acad Dermatol Venereol*, 2014, 28, s. 1016–1024.
- 20 Arican, O. – Aral, M. – Sasmaz, S., et al.: Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. *Mediators Inflamm*, 2005, 2005, s. 273–279.
- 21 Gottlieb, A. B. – Chamian, F. – Masud, S., et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. *J Immunol*, 2005, 175, s. 2721–2729.
- 22 Nijsten, T. – Wakkee, M.: Complexity of the association between psoriasis and comorbidities. *J Invest Dermatol*, 2009, 129, s. 1601–1603.

## Biologická léčba psoriázy u pacienta s latentní tuberkulózní infekcí – kazuistika

MUDr. Olga Filipovská

Kožní oddělení Masarykovy nemocnice v Ústí nad Labem, o. z., Krajská zdravotní, a. s.

- 1 van de Kerkhof, P. C. – Griffiths, C. E. – Reich, K., et al.: Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. *J Am Acad Dermatol*, 2016, 75, s. 83–97.
- 2 Chirch, L. M. – Cataline, P. R. – Dieckhaus, K. D., et al.: Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor- $\alpha$  antagonists. *J Am Acad Dermatol*, 2014, 71, s. 11e1–11e7.
- 3 Hernandez, C. – Cetner, A. S. – Jordan, J. E., et al.: Tuberculosis in the age of biologic therapy. *J Am Acad Dermatol*, 2008, 59, s. 363–380.
- 4 Cantini, F. – Nannini, C. – Niccoli, L., et al.: Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in the rheumatology and dermatology clinical practice. *Elsevier Autoimmunity Reviews*, 2015, 14, s. 503–509.
- 5 Centers for Disease Control and Prevention Tuberculosis associated with blocking agents against tumor necrosis factor- $\alpha$ . California, 2002–2003. *MMWR Morb Mortal Wkly Rep*, 2004, 53, s. 683–686.

## Obinutuzumab v iniciální léčbě starších a komorbidních nemocných s chronickou lymfocytární leukemií

prof. MUDr. Tomáš Papajík, CSc. | MUDr. Renata Urbanová, Ph.D.

Hemato-onkologická klinika LF UP a FN Olomouc

- 1 Dostupné z: <https://seer.cancer.gov/statfacts/html/cytl.html>, vyhledáno 21. 2. 2017.
- 2 Dostupné z: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cll/incidence#heading=Two>, vyhledáno 21. 2. 2017.
- 3 Zoellner, A. K. – Höhler, T. – Fries, S., et al.: Altered treatment of chronic lymphocytic leukemia in Germany during the last decade. *Ann Hematol*, 2016, 95, s. 853–861.
- 4 Pulte, D. – Redaniel, M. T. – Bird, J., et al.: Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century. *Eur J Haematol*, 2015, 94, s. 540–545.
- 5 Dostupné z: [www.ageuk.org.uk/Documents/ENGB/Factsheets/Later\\_Life\\_UK\\_factsheet.pdf?dtrk%2%BCtrue](http://www.ageuk.org.uk/Documents/ENGB/Factsheets/Later_Life_UK_factsheet.pdf?dtrk%2%BCtrue), vyhledáno 21. 2. 2017.
- 6 Reyes, C. – Satram-Hoang, S. – Hoang, K., et al.: What is the impact of comorbidity burden on treatment patterns and outcomes in elderly chronic lymphocytic leukemia patients? *Blood*, 2012, 120, s. 758.
- 7 Thurmes, P. – Call, T. – Spaget, S., et al.: Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. *Leuk Lymphoma*, 2008, 49, s. 49–56.
- 8 Extermann, M. – Hurria, A.: Comprehensive geriatric assessment for older patients with cancer. *J Clin Oncol*, 2007, 25, s. 1824–1831.
- 9 Eichhorst, B. – Fink, A. M. – Bahlo, J., et al.: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncol*, 2016, 17, s. 928–942.
- 10 Merli, F. – Mammì, C. – Ilariucci, F.: Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future. *Curr Oncol Rep*, 2015, 17, s. 31.
- 11 Fischer, K. – Bahlo, J. – Fink, A. M., et al.: Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood*, 2016, 127, s. 208–215.
- 12 Farce, A. – de Decker, L. – Pauly, V., et al.: Frailty markers and treatment decisions in patients seen in oncogeriatric clinics: results from the ASRO pilot study. *PLoS One*, 2016, 11, s. e0149732.
- 13 Huisingh-Scheetz, M. – Walston, J.: How should older adults with cancer be evaluated for frailty? *J Geriatr Oncol*, 2016, pii: S1879-4068(16)30060-1.
- 14 Hallek, M. – Cheson, B. D. – Katovsky, D., et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*, 2008, 111, s. 5446–5456.
- 15 Staudek, R. – Eichhorst, B. – Hamaker, M. E., et al.: Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. *Ann Oncol*, 1. 11. 2016, pii: mdw547.
- 16 Balducci, L. – Dolan, D.: Chronic lymphocytic leukemia in the elderly: epidemiology and proposed patient-related approach. *Cancer Control*, 2015, 22, s. 3–6.
- 17 Hamaker, M. E. – Mitrovic, M. – Stauder, R.: The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. *Ann Hematol*, 2014, 93, s. 1031–1040.
- 18 Lazarovici, C. K. R. – Leignel, D. – Fabre-Guillevin, E., et al.: Factors leading oncologists to refer elderly cancer patients for geriatric assessment. *J Geriatr Oncol*, 2011, 2, s. 194–199.
- 19 Foon, K. A. – Boyiadzis, M. – Land, S. R., et al.: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol*, 2009, 27, s. 498–503.
- 20 Smolej, L. – Brychtova, Y. – Doubek, M., et al.: Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with

- chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of Project Q-Lite by Czech CLL Study Group. *ASH Blood*, 2014, 124, s. 4670.
- 21 **Bouvet, E. – Borel, C. – Obérik, L., et al.**: Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. *Haematologica*, 2013, 98, s. 65–70.
  - 22 **Ventile, M. – Zirlik, K. – Ciolli, S., et al.**: Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. *Eur J Cancer*, 2016, 60, s. 154–165.
  - 23 **Hillmen, P. – Gribben, J. G. – Follows, G. A., et al.**: Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. *J Clin Oncol*, 2014, 32, s. 1236–1241.
  - 24 **Goede, V. – Fischer, K. – Busch, R., et al.**: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110.
  - 25 **Illidge, T. – Klein, C. – Sehn, L. H., et al.**: Obinutuzumab in hematologic malignancies: lessons learned to date. *Cancer Treat Rev*, 2015, 41, s. 784–792.
  - 26 **Smolej, L.**: Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. *Pharmgenomics Pers Med*, 2014, 8, s. 1–7.
  - 27 **Goede, V. – Klein, C. – Stilgenbauer, S.**: Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody. *Oncol Res Treat*, 2015, 38, s. 185–192.
  - 28 **Bertiny, F. – Friess, T. – Bader, S., et al.**: Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. *Leuk Lymphoma*, 2014, 55, s. 2151–2160.
  - 28 **Goede, V. – Fischer, K. – Busch, R., et al.**: Chemioimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. *Leukemia*, 2013, 27, s. 1172–1174.
  - 29 **Goede, V. – Fischer, K. – Engelse, A., et al.**: Obinutuzumab as front-line treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. *Leukemia*, 2015, 29, s. 1602–1604.
  - 30 **Michallet, A. S. – Aktan, M. – Schul, A., et al.**: Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia: primary results from the randomised phase IIIb MABLE study. XVI International Workshop on Chronic Lymphocytic Leukaemia. Sydney, Austrálie, 6.–9. 9. 2015.

## Nivolumab v léčbě Hodgkinova lymfomu – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 **Schmitz, N. – Pfister, B. – Sextro, M., et al.**: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*, 2002, 359, s. 2065–2071.
- 2 **Arai, S. – Fanale, M. – DeVos, S., et al.**: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. *Leuk Lymphoma*, 2013, 54, s. 2531–2533.
- 3 **Martinez, C. – Canals, C. – Sarina, B., et al.**: Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. *Ann Oncol*, 2013, 24, s. 2430–2434.
- 4 **Younes, A. – Gopal, A. K. – Smith, S. E., et al.**: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*, 2012, 30, s. 2183–2189.
- 5 **Yamamoto, R. – Nishikori, M. – Kitawaki, T., et al.**: PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. *Blood*, 2008, 111, s. 3220–3224.
- 6 **Ansell, S. M. – Lesokhin, A. M. – Borrello, I., et al.**: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 311–319.
- 7 **Ansell, S. M.**: Nivolumab in the treatment of Hodgkin lymphoma. *Clin Cancer Res*, 2016, 23, s. 1–5.
- 8 **Younes, A. – Santoro, A. – Shupl, M., et al.**: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1283–1294.
- 9 **Timmerman, J. – Engert, A. – Younes, A., et al.**: 1110 CheckMate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. 58<sup>th</sup> Annual Meeting & Exposition, San Diego, CA. ASH. 2016.

Komentář k článku: prof. MUDr. Marek Trněný, CSc. I. interní klinika, 1. LF UK a VFN, Praha

- 1 **Bonadonna, G. – Zucali, R. – Monfardini, S., et al.**: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. *Cancer*, 1975, 36, s. 252–259.
- 2 **Diehl, V. – Franklin, J. – Pfreundschuh, M., et al.**: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. *N Engl J Med*, 2003, 348, s. 2386–2395.
- 3 **Carde, P. – Karasch, M. – Fortpied, C., et al.**: Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in stage III to IV, international prognostic score  $\geq 3$ , high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Inter-group Trial. *J Clin Oncol*, 2016, 34, s. 2028–2036.
- 4 **Schmitz, N. – Pfister, B. – Sextro, M., et al.**: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*, 2002, 359, s. 2065–2071.
- 5 **Martinez, C. – Canals, C. – Sarina, B., et al.**: Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. *Ann Oncol*, 2013, 24, s. 2430–2434.
- 6 **Younes, A. – Gopal, A. K. – Smith, S. E., et al.**: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*, 2012, 30, s. 2183–2189.
- 7 **Roemer, M. G. – Advani, R. H. – Ligon, A. H., et al.**: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. *J Clin Oncol*, 2016, 34, s. 2690–2697.
- 8 **Ansell, S. M. – Lesokhin, A. M. – Borrello, I., et al.**: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*, 2015, 372, s. 311–319.
- 9 **Younes, A. – Santoro, A. – Shupl, M., et al.**: Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1283–1294.
- 10 **Timmerman, J. M. – Engert, A. – Younes, A., et al.**: Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. *Blood*, 2016, 128, s. 1110.
- 11 **Zinzani, P. L. – Engert, A. – Younes, A., et al.**: Checkmate 205 cohort C: Nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. *Haematologica*, 2016, 101, s. 43–44.
- 12 **Fehniger, T. A. – Larson, S. – Trinkaus, K., et al.**: A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood*, 2011, 118, s. 5119–5125.
- 13 **Cheson, B. D. – Ansell, S. – Schwarz, L., et al.**: Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. *Blood*, 2016, 128, s. 2489–2496.
- 14 **Armand, P. – Zinzani, P. L. – Collins, G. P., et al.**: Outcomes of allogeneic hematopoietic stem cell transplantation after treatment with nivolumab for relapsed/refractory Hodgkin lymphoma. *Blood*, 2016, 128, s. 3502–3502.

## Léčba mnohočetného myelomu – současné možnosti

prof. MUDr. Ivan Špička, CSc. I. interní klinika 1. LF UK a VFN, Praha

- 1 **Boyle, P. – Ferlay J.**: Cancer incidence and mortality in Europe. *Ann Oncol*, 2004, 16, s. 481–488.
- 2 **Attal, M. – Harousseau, J. L. – Stoppa, A. M., et al.**: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. *N Engl J Med*, 1996, 335, s. 91–97.
- 3 **Barlogie, B. – Mitchell, A. – van Rhee, F., et al.**: Curing myeloma at last: defining criteria and providing the evidence. *Blood*, 2014, 124, s. 3043–3051, doi: 10.1182/blood-2014-07-552059, Epub 7. 10. 2014.
- 4 **Hájek, R. – Jarkovský, J. – Maisnar, V., et al.**: Survival and treatment patterns in patients with symptomatic multiple myeloma (MM) in a real world setting. *EHA 2016*, abstrakt 1280.
- 5 **San Miguel, J. F. – Schlag, R. – Khuageva, N. K., et al.**: VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med*, 2008, 359, s. 906–917.
- 6 **Stewart, A. K. – Rajkumar, S. V. – Dimopoulos, M. A., et al.**: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*, 2015, 372, s. 142–152, doi: 10.1056/NEJMoa1411321, Epub 6. 12. 2014.
- 7 **Mele, G. – Giannotta, A. – Pinna, S., et al.**: Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide. *Leukemia & lymphoma*, 2010, 51, s. 937–940.
- 8 **Castelli, R. – Pantaler, G. – Gallipoli, P., et al.**: Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. *Anti-cancer drugs*, 2015, 26, s. 1078–1082.
- 9 **Rodon, P. – Hulin, C. – Pegourie, B., et al.**: Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. *Haematologica*, 2015, 100, s. e56–e59.
- 10 **Azarm, T. – Akbari, M. – Azarm, A., et al.**: Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma. *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*, 2012, 17, s. 8–14.
- 11 **Dimopoulos, M. A. – Moreau, P. – Palumbo, A., et al.**: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncology*, 2016, 17, s. 27–38.
- 12 **Dytfeld, D. – Jasielc, J. – Griffith, K. A., et al.**: Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. *Haematologica*, 2014, 99, s. e162–e164.
- 13 **Avet-Loiseau, H. – Fonseca, R. – Siegel, D., et al.**: Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. *Blood*, 2016, 128, s. 1174–1180, doi: 10.1182/blood-2016-03-707596.
- 14 **Stewart, A. K. – Dimopoulos, M. A. – Masszi, T. – Špička, I., et al.**: Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. *J Clin Oncol*, 2016, pii: JCO669648.
- 15 **Orlowski, R. Z. – Ghercheva, L. – Williams, C., et al.**: A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. *Am J Hematol*, 2015, 90, s. 42–49, doi: 10.1002/ajh.23868.
- 16 **Lokhorst, H. M. – Plesner, T. – Laubach, J. P., et al.**: Targeting CD38 with daratumumab monotherapy in multiple myeloma. *N Engl J Med*, 2015, 373, s. 1207–1219.
- 17 **Lonial, S. – Weiss, B. M. – Usmani, S. Z., et al.**: Daratumumab

- monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet*, 2016, 387, s. 1551–1560.
- 18 **Palumbo, A.** – Chanan-Khan, A. – Seidel, K., et al.: CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 375, s. 754–766, doi: 10.1056/NEJMoa1606038.
- 19 **Lonial, S.** – Kaufman, J. – Reece, D., et al.: Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. *Expert Opin Biol Ther*, 2016, 16, s. 1291–1301, doi: 10.1080/14712598.2016.1221920, Epub 17. 8. 2016.
- 20 **Lonial, S.** – Dimopoulos, M. – Palumbo, A., et al.: ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med*, 2015, 373, s. 621–631, doi: 10.1056/NEJMoa1505654, Epub 2. 6. 2015.
- 21 **Kumar, S. K.** – Bensinger, W. I. – Zimmermann, T. M., et al.: Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. *Blood*, 2014, 124, s. 1047–1055, doi: 10.1182/blood-2014-01-548941.
- 22 **Moreau, P.** – Masszi, T. – Grzasko, N., et al.: TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 374, s. 1621–1634, doi: 10.1056/NEJMoa1516282.
- 23 **Richardson, P. G.** – Mitsiades, C. S. – Laubach, J. P. – Hajek, R. – Spicka, I., et al.: Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. *Leuk Res*, 2013, 37, s. 829–837, doi: 10.1016/j.leukres.2013.03.006, Epub 9. 4. 2013.
- 24 **Dimopoulos, M.** – Siegel, D. S. – Lonial, S., et al.: Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. *Lancet Oncol*, 2013, 14, s. 1129–1140.
- 25 **San-Miguel, J. F.** – Hungria, V. T. – Yoon, S. S., et al.: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1195–1206.
- 26 **Kantarjian, H. M.** – Fojo, T. – Mathisen, M. – Zwelling, L. A.: Cancerdrugs in the United States: Justum Pretium – the just price. *J Clin Oncol*, 2013, 31, s. 3600–3604, doi: 10.1200/JCO.2013.49.1845, Epub 6. 5. 2013.
- 27 **Mitsiades, C. S.** – Davies, F. E. – Laubach, J. P., et al.: Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. *J Clin Oncol*, 10. 5. 2011, 29, s. 1916–1923, doi.org/10.1016/j.jco.2012.11.002.
- 28 **Palumbo, A.** – Avet-Loiseau, H. – Oliva, S., et al.: Revised international staging system for multiple myeloma: a report from International myeloma working group. *J Clin Oncol*, 2015, 33, s. 2863–2869, doi: 10.1200/JCO.2015.61.2267, Epub 3. 8. 2015.
- 29 **Giralt, S.** – Garderet, L. – Durie, B., et al.: American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group: Consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. *Biol Blood Marrow Transplant*, 2015, 21, s. 2039–2051, doi: 10.1016/j.bbmt.2015.09.016, Epub 30. 9. 2015.

## Biosimilární rituximab – GP2013 – Lékový profil

MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové

- 1 **McLaughlin, P.**, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncol*, 1998, 16, s. 2825–2833.
- 2 **Coiffier, B.**, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med*, 2002, 346, s. 235–242.
- 3 **Eichhorst, B. F.**, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. *Blood*, 2006, 107, s. 885–891.
- 4 **Visser, J.**, et al.: Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. *BioDrugs*, 2013, 27, s. 495–507, doi: 10.1007/s40259-013-0036-33.
- 5 **da Silva, A.**, et al.: Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. *Leuk Lymphoma*, 2014, 55, s. 1609–1617, doi: 10.3109/10428194.2013.843090.

## Možnosti léčby metastazujícího melanomu v kazuistikách

MUDr. Ivana Krajsová, MBA Kožní klinika VFN a 1. LF UK, Praha

- 1 **Davey, J. R.** – van der Westhuizen, A. – Bowden, N. A.: Metastatic melanoma treatment: Combining old and new therapies. *Critical Reviews in Oncology/Hematology*, 2016, 98, s. 242–253.
- 2 **Chapman, P. B.** – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- 3 **Hauschild, A.** – Grob, J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre open-label phase 3 randomized controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 4 **Long, G. V.** – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*, 2014, 371, s. 1877–1888.
- 5 **Long, G. V.** – Weber, J. S. – Infante, J. R., et al.: Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. *J Clin Oncol*, 2016, 34, s. 871–878.
- 6 **Ribas, A.** – Puzanov, I. – Dummer, R., et al.: Pembrolizumab versus investigator choice chemotherapy for ipilimumab refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. *Lancet Oncol*, 2015, 16, s. 908–918.
- 7 **Robert, C.** – Long, V. G. – Brady, B., et al.: Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*, 2015, 372, s. 320–330.
- 8 **Weber, S. J.** – D'Angelo, S. P. – Minor, D., et al.: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open label phase 3 trial. *Lancet Oncol*, 2015, 16, s. 375–384.
- 9 **Robert, C.** – Schachter, J. – Long, G. V., et al.: Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med*, 2015, 372, s. 2521–2532.
- 10 **Mahoney, M. K.** – Atkins, M. B.: Prognostic and predictive markers for the new immunotherapies. *Oncology*, 2014, suppl. 3, s. 39–48.
- 11 **Daud, A. I.** – Wolchok, J. D. – Robert, C., et al.: Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. *J Clin Oncol*, 2016, 34, s. 4102–4109, Epub 31. 10. 2016.
- 12 **Redman, J. M.** – Gibney, G. T. – Atkins, M. B.: Advances in immunotherapy for melanoma. *BMC medicine*, 2016, doi:10.1186/s12916-016-0571-0.
- 13 **Kwong, A.** – Sanlorenzo, M. – Rappersberger, K., et al.: Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. *Wien Med Wochenschr*, 13. 1. 2017, doi: 10.1007/s10354-016-0535-1, Epub před tiskem.
- 14 **Ribas, A.** – Kim, K. B. – Schuchter, L. M., et al.: BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. 2011 ASCO Annual Meeting. *J Clin Oncol*, 2011, 29, suppl., abstrakt 8509.

## Biologická léčba karcinomu prsu aktuálně

MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- 1 **Jerusalem, G.** – Bachelor, T. – Barrios, C., et al.: A new era of improving progression-free survival with dual blockade in postmenopausal HR (+), HER2 (-) advanced breast cancer. *Cancer Treat Rev*, 2015, 41, s. 94–104.
- 2 **Yardley, D. A.** – Noguchi, S. – Pritchard, K. I., et al.: Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis. *Adv Ther*, 2013, 30, s. 870–884.
- 3 **Piccart, M.** – Hortobagyi, G. – Campono, M., et al.: Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. *Ann Oncol*, 2014, 25, s. 2357–2362.
- 4 **Kornblum, N. S.** – Manola, J. – Klein, P., et al.: PreCOG 0102: A randomized, double blind, Phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy. 2016 San Antonio Breast Cancer Symposium, abstrakt S1-02, prezentováno 7. 12. 2016.
- 5 **Finn, R. S.** – Martin, M. – Rugo, H. S., et al.: A randomized, multicenter, double-blind phase 3 study of Pd-0332991 (Oral Cdk 4/6 Inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER (+), Her2 (-) breast cancer who have not received any prior systemic anti cancer treatment for advanced disease. *N Engl J Med*, 2016, 375, s. 1925–1936.
- 6 **Cristofanilli, M.** – Turner, N. C. – Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- 7 **Ismael, G.** – Hegg, R. – Melichar, B., et al.: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. *Lancet Oncol*, 2012, 13, s. 869–878.
- 8 **Gianni, L.** – Pienkowski, T. – Im, Y. H., et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*, 2016, 17, s. 791–800.
- 9 **Swain, S. M.** – Kim, S. B. – Cortés, J., et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol*, 2013, 14, s. 461–471.
- 10 **Krop, I. E.** – Lin, N. U. – Blackwell, K., et al.: Trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. *Ann Oncol*, 2015, 26, s. 113–119.
- 11 **Cameron, D.** – Casey, M. – Oliva, C., et al.: Lapatinib plus capecitabine in women with HER2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. *Oncologist*, 2010, 15, s. 924–934.
- 12 **Dirix, L. Y.** – Takacs, I. – Nikolinakos, P., et al.: Abstracts 1-04: Avelumab (Msb0010718c), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase IB javelin solid tumor

trial. *Cancer Res*, 2016, 76.  
13 **Adams, S. – Diamond, J. – Hamilton, E., et al.**: Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL-1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. *Cancer Res*, 2016, 76.

14 **Rugo, H. S. – Delord, J. P. – Im, S. A., et al.**: Abstract 55-07: Preliminary efficacy and safety of pembrolizumab (MK3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER- negative advanced breast cancer enrolled in Keynote-028. *Cancer Res*, 2016, 76.  
15 **Traina, T. A. – Miller, K. – Yardley, D. A., et al.**: Results from a phase 2

study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). *J Clin Oncol*, 33, suppl.

## Palbociclib v kombinaci s letrozolem v léčbě diseminovaného karcinomu prsu

MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno

1 **Finn, R. S., et al.**: Palbociclib and letrozole in advanced breast cancer. *New England Journal of Medicine*, 2016, 375, s. 1925–1936.  
2 **Cardoso, F., et al.**: 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). *The Breast*, 2017, 31, s. 244–259.  
3 **Finn, R. S., et al.**: The cyclin-dependent kinase 4/6 inhibitor

palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *The Lancet Oncology*, 2015, 16, s. 25–35.

4 **Cristofanilli, M., et al.**: Fulvestrant plus palbociclib versus fulvestrant

plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *The Lancet Oncology*, 2016, 17, s. 425–439.

Komentář k článku: MUDr. Katarína Petraková, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno

1 **Rugo, H. S. – Rumble, R. B. – Macese, E., et al.**: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. *J Clin Oncol*, 2016, 34, s. 3069–3103.  
2 **Patnaik, A. – Rosen, L. S. – Tolaney, S. M., et al.**: Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast

cancer, non-small cell lung cancer, and other solid tumors. *Cancer Discov*, 2016, 6, s. 740–753.

3 **Cristofanilli, M. – Turner, N. C. – Bondarenko, I., et al.**: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that

progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.

## Osimertinib – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

1 **Greig, S. L.**: Osimertinib: first global approval. *Drugs*, 2016, 76, s. 263–273.  
2 **Inlay, M. R. – Anderson, M. – Ashton, S., et al.**: Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. *J Med Chem*, 2014, 57, s. 8249–8267.  
3 **Peters, S. – Zimmermann, S. – Adjei, A. A.**: Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. *Cancer Treat Rev*, 2014, 40, s. 917–926.  
4 **Nguyen, K. S. – Neal, J. W. – Wakelee, H.**: Review of the current targeted therapies for non-small-cell lung cancer. *World J Clin Oncol*, 2014, 5, s. 576–587.  
5 **Novello, S. – Barlesi, F. – Califano, R., et al.**: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis,

treatment and follow-up. *Ann Oncol*, 2016, 27, s. v1–v27.

6 **Gross, D. A. – Ashton, S. E. – Ghiorghiu, S., et al.**: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discov*, 2014, 4, s. 1046–1061.

7 **Brown, K. – Comisar, C. – Witjes, H., et al.**: Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. *Br J Clin Pharmacol*, 2016.

8 **Planchard, D. – Brown, K. H. – Kim, D. W., et al.**: Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. *Cancer Chemother Pharmacol*, 2016, 77, s. 767–776.

9 **Skoulidis, F. – Papadimitrakopoulou, V. A.**: Targeting the gatekeeper: osimertinib in EGFR T790M mutation-positive non-small cell lung cancer. *Clin Cancer Res*, 2017, 23, s. 618–622.

10 **Goss, G. – Tsai, C. M. – Shepherd, F. A., et al.**: Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*, 2016, 17, s. 1643–1652.

11 **Janne, P. A. – Yang, J. C. – Kim, D. W., et al.**: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 1689–1699.

12 **Mok, T. S. – Wu, Y. I. – Ahn, M. J., et al.**: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.

13 **Nie, K. K. – Zou, X. – Geng, C. X., et al.**: AZD9291-induced acute interstitial lung disease. *Chin Med J (Engl)*, 2016, 129, s. 1507–1508.

14 **Remon, J. – Planchard, D.**: AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. *Future Oncol*, 2015, 11, s. 3069–3081.

## Monoklonální protilátky v léčbě nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha

1 **Sander, A., et al.**: Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*, 2006, 355, s. 2542–2550.  
2 **Garon, E. B. – Ciuleanu, T. E. – Arrieta, O., et al.**: Ramucicromab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 2014, 384, s. 665–673.  
3 **Thatcher, N. – Hirsch, F. R. – Luft, A. V., et al.**: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncology*, 2015, 16, s. 763–774.  
4 **Pirker, R. – Pereira, J. R. – Szczesna, A., et al.**: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet*, 2009, 373, s. 1525–1531.  
5 **Spigel, D. R., et al.**: A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs. docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small

cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33 (suppl.), abstrakt 8009.

6 **Paz-Ares, L. – Horn, L. – Borghaei, H., et al.**: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33 (suppl.), abstrakt LBA109.

7 **Borghaei, H. – Brahmer, J. R. – Horn, L.**: Nivolumab (nivo) vs. docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. *J Clin Oncol*, 2016, 34 (suppl.), abstrakt 9025.

8 **Garon, E. B. – Jizvi, N. A. – Hui, R., et al.**: KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 2018–2028, doi: 10.1056/NEJMoa1501824.

9 **Herbst, R. S. – Kim, D. W. – Felip, E., et al.**: KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs. docetaxel for PD-L1-positive NSCLC after platinum-based therapy. Prezentováno na kongresu ESMO Asia 2015, Singapur, 18.–21. 12. 2015, LBA3 PR.

10 **Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.**: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.

11 **Barlesi, F.**: Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. ESMO 2016 Presidential Symposium 2, 9. 10. 2016, abstrakt LBA44\_PR.

12 **Clarke, J. M. – Hurwitz, H. I.**: Targeted inhibition of VEGF receptor 2: an update on ramucicromab. *Expert Opin Biol Ther*, 2013, 13, s. 1187–1196.

13 **Portrazza EU SPC**, dostupné z: [http://www.ema.europa.eu/docs/cs\\_CZ/document\\_library/EPAR\\_-\\_Product\\_Information/human/003886/WC500202694.pdf](http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003886/WC500202694.pdf), vyhledáno 10. 1. 2017.

14 **Brahmer, J. – Reckamp, K. L. – Baas, P., et al.**: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.

15 **Herbst, R. S. – Baas, P. – Kim, D. W., et al.**: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*, 2015, Epub před tiskem.

16 **Herbst, R. S. – Baas, P. – Kim, D., et al.**: Pembrolizumab (pembro) vs docetaxel (docel) for previously treated, PD-L1-expressing NSCLC: Updated outcomes of KEYNOTE-010. ESMO 2016, prezentace, abstrakt LBA48.

# Alectinib – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Lockney, N. A. – Wu, A. J.: Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases. *J Thorac Dis*, 2017, 9, s. E152–E154.
- 2 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 3 Holla, V. R. – Elamin, Y. Y. – Bailey, A. M., et al.: ALK: a tyrosine kinase target for cancer therapy. *Cold Spring Harb Mol Case Stud*, 2017, 3, s. a001115.
- 4 Kodama, T. – Tsukaguchi, T. – Yoshida, M., et al.: Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. *Cancer Lett*, 2014, 351, s. 215–221.
- 5 Kodama, T. – Tsukaguchi, T. – Satoh, Y., et al.: Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. *Mol Cancer Ther*, 2014, 13, s. 2910–2918.
- 6 Kodama, T. – Hasegawa, M. – Takanashi, K., et al.: Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. *Cancer Chemother Pharmacol*, 2014, 74, s. 1023–1028.
- 7 Seto, T. – Kiura, K. – Nishio, M., et al.: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. *Lancet Oncol*, 2013, 14, s. 590–598.
- 8 Gadgeel, S. M. – Shaw, A. T. – Govindan, R., et al.: Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. *J Clin Oncol*, 2016, 34, s. 4079–4085.
- 9 Shaw, A. T. – Sandhi, L. – Gadgeel, S., et al.: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 234–242.
- 10 Ou, S. H. – Ahn, J. S. – De Petris, L., et al.: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. *J Clin Oncol*, 2016, 34, s. 661–668.
- 11 Kwok, W. C. – Tam, T. C. – Lui, M. M., et al.: Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancer. *Respir Case Rep*, 2017, 5, s. e00224.
- 12 Zhu, V. – Ou, S. H.: Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. *Expert Opin Drug Saf*, 2017, s. 1–6.
- 13 FDA (2016). Clinical pharmacology and biopharmaceutics review(s) of alectinib. US Food and Drug Administration. Dostupné z: [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/208434Orig1s000ClinPharmR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/208434Orig1s000PharmR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000PharmR.pdf), vyhledáno 4. 2. 2016.
- 14 SPC přípravku Alecensa.

## Renální karcinom – novinky v biologické léčbě 2016

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, 2005, dostupné z: [www.svod.cz](http://www.svod.cz), vyhledáno 25. 12. 2016.
- 2 Choueiri, T. K. – Escudier, B. – Powles, T., et al.: Cabozantinib versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1814–1823.
- 3 Motzer, R. J. – Hutson, T. E. – Glen, H., et al.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*, 2015, 16, s. 1473–1482.
- 4 Rini, B. I. – Stenzl, A. – Zdrojowy, R., et al.: IMA901, a multipetide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 1599–1611.
- 5 Motzer, R. J. – Escudier, B. – McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.
- 6 Cella, D. – Grünwald, V. – Nathan, P., et al.: Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 994–1003.
- 7 Haas, N. B. – Manola, J. – Uzzo, R. G., et al.: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet*, 2016, 387, s. 2008–2016.
- 8 Chamie, K. – Donin, N. M. – Klöpfer, P., et al.: Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: The ARISER randomized clinical trial. *JAMA Oncol*, 2016, doi: 10.1001/jamaoncol.2016.4419.
- 9 Ravaud, A. – Motzer, R. J. – Pandha, H. S., et al.: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. *N Engl J Med*, 9. 10. 2016.

## Biologická léčba kolorektálního karcinomu

MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno

- 1 Gill, S. – Blackstock, A. W. – Goldberg, R. M.: Colorectal cancer. *Mayo Clin Proc*, 2007, 82, s. 114–129.
- 2 Lukas, A. S. – O'Neil, B. H. – Goldberg, R. M.: A decade of advanced in cytotoxic chemotherapy for metastatic colorectal cancer. *Clin Colorectal Cancer*, 2011, 10, s. 238–244.
- 3 Folkman, J. – Merler, E. – Abernathy, C., et al.: Isolation of a tumor factor responsible for angiogenesis. *J Exp Med*, 1971, 133, s. 275–288.
- 4 Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*, 2004, 350, s. 2335–2342.
- 5 Giantonio, B. J. – Catalano, P. J. – Meropol, N. J., et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol*, 2007, 25, s. 1539–1544.
- 6 Tew, W. P. – Gordon, M. – Murren, J., et al.: Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumors. *Clin Cancer Res*, 2010, 16, s. 358–366.
- 7 Van Cutsem, E. – Tabernero, J. – Lakomy, R., et al.: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*, 2012, 30, s. 3499–3506.
- 8 Tabernero, J. – Van Cutsem, E. – Lakomy, R., et al.: Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial.
- 9 Masui, H. – Kawamoto, T. – Sato, J. D., et al.: Growth inhibition of human tumor cell in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. *Cancer Rev*, 184, 44, s. 1002–1007.
- 10 Van Cutsem, E. – Kohne, C. H. – Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med*, 2009, 360, s. 1408–1417.
- 11 Van Cutsem, E. – Kohne, C. H. – Lang, I., et al.: Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol*, 2011, 29, s. 2011–2019.
- 12 Douillard, J. Y. – Siena, S. – Cassidy, J., et al.: Randomized phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol*, 2010, 28, s. 4697–4705.
- 13 Maughan, T. S. – Adams, R. A. – Smith, C. G., et al.: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of randomised phase 3 MRC COIN trial. *Lancet*, 2011, 377, s. 2103–2114.
- 14 Tveit, K. M. – Guren, T. – Glimelius, B., et al.: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol*, 2012, 30, s. 1755–1762.
- 15 Heinemann, V. – von Weikersthal, L. – Decker, T., et al.: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. *J Clin Oncol*, 2013, 31 (suppl).
- 16 Falkone, A. – Cremonini, C. – Masi, G., et al.: FOLFOX/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group. *J Clin Oncol*, 2013, 31 (suppl), abstrakt 3505.
- 17 Schwartzberg L. S. – Rivera, F. – Karthaus, M., et al.: Analysis of KRAS/NRAS mutations in PEAK: a randomized study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). *J Clin Oncol*, 2013, 31 (suppl), abstrakt 3505.
- 18 Gustavsson, B. – Carlsson, G. – Machover, D., et al.: A review of the evolution of systemic chemotherapy in the management of colorectal cancer. *Clinical Colorectal Cancer*, 2015, 14, s. 1–10.
- 19 Missiaglia, E. – Jacobs, B. – D'Ario, G., et al.: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. *Ann Oncol*, 2014, 25, s. 1995–2001.
- 20 Holch, J. W. – Richard, I. – Stintzing, S., et al.: The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *EJC*, 2017, 70, s. 87–98.
- 21 Outcome in CALGB 80405. Přednášející: H. Lenz, dostupné z: <https://slide.ctimeetingtech.com/library/esmo/browse/search/p#-2z95y02nD>, vyhledáno 5. 1. 2017.
- 22 Wang, F. – Bai, L. – Liu, T. S., et al.: Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. *Chin J Cancer*, 2015, 34, s. 384–393.
- 23 Outcome according to left vs. right side in the panitumumab studies. Přednášející: M. Peeters, dostupné z: <https://slide.ctimeetingtech.com/library/esmo/browse/search/p#2z95y02nD>, vyhledáno 5. 1. 2017.
- 24 Grothey, A. – Van Cutsem, E. – Sobrero, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 303–312.
- 25 Allegro, C. J. – Yothers, G. – O'Connell, M. J., et al.: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. *J Clin Oncol*, 2011, 29, s. 11–16.
- 26 Alberts, S. R. – Sargent, D. J. – Nair, S., et al.: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA*, 2012, 307, s. 1383–1393.



# Biologická léčba roztroušené sklerózy

doc. MUDr. Radomír Taláb, CSc. Neurologická klinika LF UK a FN Plzeň  
MUDr. Marika Talábová Neurologická klinika LF UK a FN Hradec Králové

- Comi, G. – Filippi, M. – Dolinsky, J. S.: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effect of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. *Ann Neurol*, 2001, 49, s. 290–297.
- Boneschi, F. – Rovaris, M. – Johnson, K. P., et al.: Effect of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomised, placebo-controlled clinical trials. *Mult Scler*, 2003, 9, s. 349–355.
- Comi, G. – Martinelli, V. – Rodegher, M., et al.: PreCISE study group. Effect of glatiramer acetate on conversion to clinically definitive multiple sclerosis in patients with clinically isolated syndrome (PreCISE study): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2009, 374, s. 1503–1511.
- Devonshire, V. – Lapierre, Y. – Macdonell, R., et al.: The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. *Eur J Neurol*, 2010, 18, s. 69–77.
- Ivanova, J. I. – Bergman, R. E. – Birnbaum, H. G., et al.: Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. *J Med Econ*, 2012, 15, s. 601–609.
- Taláb, R.: Glatiramer acetát v České republice – výstupy z registru ReMuS. *Remedia*, 2017, 27, s. 1–6.
- Khan, O. – Rieckmann, P. – Boyko, A., et al.: Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. *Ann Neurol*, 2013, 73, s. 705–713.
- Comi, G. – Cohen, J. A. – Arnold, D. L., et al.: Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. *Ann Neurol*, 2011, 69, s. 75–82.
- Kieseier, B. C. – Calabresi, A.: Pegylation of Interferon  $\beta$ -1a. A promising strategy in multiple sclerosis. *CNS Drugs*, 2012, 26, s. 205–214.
- Calabresi, P. A. – Kieseier, B. C. – Arnold, D. L., et al.: ADVANCE Study Investigators: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. *Lancet Neurology*, 2014, 13, s. 657–665.
- Kieseier, B. C. – Arnold, D. L. – Balcar, L. J., et al.: Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. *Mult Scler J*, 2014, s. 1–11. Dostupné z: <http://msj.sagepub.com>, vyhledáno 1. 3. 2017.
- Wiendl, H. – Gross, C. C.: Modulation of IL-2R $\alpha$  with daclizumab for treatment of multiple sclerosis. *Neurology*, 2013, 9, s. 394–404.
- Gorman, M. P. – Tillema, J. M. – Ciliax, A. M., et al.: Daclizumab use in patients with pediatric multiple sclerosis. *Arch Neurol*, 2012, 69, s. 78–81.
- Gold, R. – Giovannoni, G. – Selmaj, K., et al.: for the SELECT study investigators: Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2013, 381, s. 2167–2175.
- Giovannoni, G. – Gold, R. – Selmaj, K., et al.: For the SELECTION Study Investigators: Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. *Lancet*, 2014, 13, s. 472–481.
- Milo, R.: The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. *Ther Adv Neurol Disorders*, 2014, 7, s. 7–21.
- Kappos, L. – Wiendl, H. – Selmaj, K., et al.: Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. *NEJM*, 2015, 373, s. 1418–1428.

# Biologická léčba hypercholesterolemie

prof. MUDr. Richard Češka, CSc. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha |  
Ing. Lucie Votavová ScreenPro FH, z. s., Praha | MUDr. Michaela Šnejdrová, Ph.D. |  
MUDr. Martina Václavová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha |  
Ing. Tatjana Aleksičová ScreenPro FH, z. s., Praha | doc. MUDr. Michal Vrablík, Ph.D.  
Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- Nicholls, S. J. – Puri, R. – Anderson, T., et al.: Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLA-GOV Randomized Clinical Trial. *JAMA*, 2016, 316, s. 2373–2384.
- Češka, R., et al.: *Familární hypercholesterolemie*. TRITON, Praha, 2015.
- Christopher, P. – Canon, C. P. – Blazing, M. A., et al.: for the IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.
- Catapano, A. L. – Reiner, Z. – De Backer, G., et al.: ESC/EAS Guidelines for the management of dyslipidaemias. *Atherosclerosis*, 2011, 217, s. 3–46.
- Sahebkar, A. – Watts, G. F.: New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. *Clin Ther*, 2013, 35, s. 1082–1098.
- Kastelein, J. J. – Wedel, M. K. – Baker, B. F., et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. *Circulation*, 2006, 114, s. 1729–1735.
- Horton, J. D. – Cohen, J. C. – Hobbs, H. H.: PCSK9: a convertase that coordinates LDL catabolism. *J Lipid Res*, 2009, 50, s. S172–S177.
- Cohen, C. J. – Boerwinkle, E. – Mosley, T. H., et al.: Sequence variations in PCSK9, low LDL and protection against coronary heart disease. *N Engl J Med*, 2006, 354, s. 1264–1272.
- Stein, E. A. – Melis, S. – Yancopoulos, G. D., et al.: Effect of monoclonal antibody to PCSK9 on plasma LDL cholesterol. *N Engl J Med*, 2012, 366, s. 1108–1118.
- Ference, B. A. – Yoo, W. – Alesh, I., et al.: Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol*, 2012, 60, s. 2631–2639.
- Chan, J. C. – Piper, D. E. – Cao, Q., et al.: Beyond LDL cholesterol, a new role for PCSK9. *Proc Natl Acad Sci USA*, 2009, 106, s. 9820–9825.
- Lipinski, C. A., et al.: Effect of treatment with PCSK9 inhibition, ezetimibe, or both on 5 lipid measures. *EJH* 2016.
- Goldberg, A. C.: Novel therapies and new targets of treatment for familial hypercholesterolemia. *J Clin Lipidol*, 2010, 4, s. 350–356.

# Hepatitida C – lékové interakce přímo působících antihepatitik

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- German, P. – Yang, J. – West, S., et al.: Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet. Abstrakt P\_15, prezentováno na 15<sup>th</sup> International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 2014.
- Abbvie Corporation: *Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) Prescribing Information*. North Chicago, IL prosinec 2014.
- Talavera Pons, S. – Boyer, A. – Lamblin, G., et al.: Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. *Br J Clin Pharmacol*, 16. 8. 2016, doi: 10.1111/bcp.13095.
- Ueda, Y. – Kaido, T. – Uemoto, S.: Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation. *Transpl Int*, 2015, 28, s. 251–252.
- Fontana, R. J. – Hughes, E. A. – Bifano, M., et al.: Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. *Am J Transplant*, 2013, 13, s. 1601–1605.
- Sekar, V. – Verloes, R. – Meyvisch, P., et al.: Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. Abstrakt 1076, prezentováno na 45. výročním zasedání European Association for the Study of the Liver (EASL), Vídeň, Rakousko, 2010.
- Ouwwerkerk-Mahadevan, S. – Simion, A. – Peeters, M., et al.: Summary of pharmacokinetic drug–drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A protease inhibitor. Abstract PE 1077, prezentováno na 14<sup>th</sup> European AIDS Conference, Brusel, Belgie, 2013.
- Eley, T. – You, X. – Wang, R., et al.: Daclatasvir: overview of drug–drug interactions with antiretroviral agents and other common concomitant drugs. Abstrakt, prezentováno na HIV DART, Miami, FL, 2014.
- Menon, R. M. – Badri, P. S. – Wang, T., et al.: Drug–drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. *J Hepatol*, 2015, 63, s. 20–29.
- Karageorgopoulos, D. E. – El-Sherif, O. – Bhagani, S., et al.: Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. *Curr Opin Infect Dis*, 2014, 27, s. 36–45.
- Gane, E. – Robson, R. – Bonacini, M., et al.: Safety antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Abstrakt, prezentováno na 65. výročním zasedání American Association for the Study of Liver Diseases (AASLD), Boston, MA, 2014.